Fatores prognósticos e histopatológicos do osteossarcoma canino e correlação com a sobrevida
Ano de defesa: | 2019 |
---|---|
Autor(a) principal: | |
Orientador(a): | |
Banca de defesa: | |
Tipo de documento: | Dissertação |
Tipo de acesso: | Acesso aberto |
Idioma: | por |
Instituição de defesa: |
Universidade Federal de Minas Gerais
Brasil VETER - ESCOLA DE VETERINARIA Programa de Pós-Graduação em Ciência Animal UFMG |
Programa de Pós-Graduação: |
Não Informado pela instituição
|
Departamento: |
Não Informado pela instituição
|
País: |
Não Informado pela instituição
|
Palavras-chave em Português: | |
Link de acesso: | http://hdl.handle.net/1843/30448 |
Resumo: | Osteosarcoma is the most common primary bone tumor in dogs. It is a locally aggressive, rapidly evolving disease with metastatic features. This dissertation aimed to characterize the canine population diagnosed with osteosarcoma at the UFMG Veterinary Hospital from 2013 to 2018, through a survey of clinical, epidemiological, histopathological and immunohistochemical data in order to characterize prognostic factors and their impact on survival treated and untreated animals. 43 cases of OSA were studied and histopathologically diagnosed by the pathology sector of HV-UFMG. In the present study, the age of the dogs ranged from 1 to 15 years, being the average 7.94 ± 3.43 years, and the most frequent location was in the appendicular skeleton of pure breed and large dogs. There was a correlation between physical size and overall survival, as well as between the elevated level of serum alkaline phosphatase and a lower overall survival. In the histopathological evaluation, the most common subtype was osteoblastic, and the tumor grade showed a positive and marginally significant correlation with the cell proliferation index (ki67). There was a statistically significant difference in the evaluation of the overall survival of animals treated with only surgery, with a total of 21 cases with average 60 days, in contrast with 15 cases where there was complementation with adjuvant chemotherapy, which presented na average of 455 days. |